Division of Gastroenterology, McGill University Health Center, Montreal General Hospital, McGill University, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.
Division of Gastroenterology, McGill University Health Center, Montreal General Hospital, McGill University, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.
Gastroenterol Clin North Am. 2017 Sep;46(3):645-659. doi: 10.1016/j.gtc.2017.05.014.
In patients with Crohn's disease on biologic medications, the use of therapeutic drug monitoring leads to a personalized approach to optimize treatment. Using an algorithmic approach, measurement of drug concentrations and anti-drug antibodies can be used to improve treatment outcomes. Therapeutic drug concentrations and absence of antibodies are associated with improved clinical and endoscopic outcomes. In clinical practice, therapeutic drug monitoring has been shown to be clinically useful and cost-effective in patients experiencing a loss of response to treatment. This review highlights the available data on therapeutic drug monitoring in the treatment of patients with Crohn's disease on biologic medications.
在接受生物药物治疗的克罗恩病患者中,治疗药物监测的应用可实现个体化治疗优化。通过算法方法,可以测量药物浓度和抗药物抗体,以改善治疗结果。治疗药物浓度和无抗体与改善的临床和内镜结果相关。在临床实践中,治疗药物监测已被证明在治疗反应丧失的患者中具有临床实用性和成本效益。本综述强调了生物药物治疗克罗恩病患者的治疗药物监测的现有数据。